ROYESH-SCB R&D Approach

ROYESH-SCB Institute always strives to create its R&D approach comprehensive, interdisciplinary, and aligned with the best methods and international guidelines. Below is an outlined strategy, reflecting our insight.

1. Fundamental & Applied Research Themes

  • Fundamental Biotechnology

    Investigating self-renewal, pluripotency, differentiation, and the molecular mechanisms underlying stem cell states (e.g., pluripotent, adult, disease-associated stem cells).

  • Disease Modeling

    Using induced pluripotent stem cells (iPSCs) and organoids to create in vitro models for genetic diseases, malignancy, and regenerative failure.

  • Therapeutic Development

    Translating research into clinical-grade cell therapies, prioritizing safety, efficacy, and scalability. Develop cell and gene therapies for congenital defects, immune disorders, and degenerative diseases.

2. Technology Development & Innovation

  • Bioprocess Design

    Developing automated, scalable protocols for stem cell expansion, differentiation, and characterization to enable robust and reproducible manufacturing.

  • Biomaterial Science

    Designing biomaterials and scaffolds that enhance cell culture, differentiation, and integration in tissue engineering applications.

3. Quality, Standards & Compliance

  • Standardization

    Implementation of validated SOPs, rigorous quality control, and reproducibility checks for all research and cell manufacturing processes.

  • Ethical Oversight

    Following international guidelines such as ISSCR recommendations, focusing on transparency, patient welfare, informed consent, and data integrity.

  • Long-term Monitoring

    For clinical translation, include long-term tracking of outcomes, adverse effects, and reporting of results (positive, negative, or inconclusive).

4. Collaboration & Multi-disciplinarility

  • Academic & Clinical Partnerships:

    Integrating basic, translational, and clinical research with strategic collaborations between academia, clinics, and industry to expedite innovation and application.

  • Interdisciplinary Teams

    Fostering a community of biologists, clinicians, bioengineers, geneticists, and data scientists to address complex problems from multiple angles.

  • Shared Infrastructure

    Leveraging core facilities and technology platforms for stem cell characterization, genome manipulation, and omics approaches.

5. Translational Pipeline

  • Preclinical Validation

    Performing comprehensive preclinical studies (disease models, efficacy, safety/toxicity) before proceeding to human trials.

  • Clinical Trials

    Designing carefully phased clinical studies, emphasizing gradual risk escalation, patient protection, rigorous controls, and competitive effectiveness assessment.

  • Regulatory Engagement:

    Liaising early with health regulatory authorities to ensure compliance, address biosafety, and facilitate product approval pathways.